The IT of GBA Pharma GmbH has successfully obtained certification according to ISO/IEC 27001 – the internationally recognized standard for information security management systems (ISMS). The certification covers the IT infrastructure supporting the sites Pharmacelsus GmbH, ABF Pharmaceutical Services GmbH, GBA Medical Device Services GmbH, as well as KaLy-Cell. The successful ISO/IEC 27001 certification demonstrates that information security is deeply embedded in the structures of GBA Group’s Pharma division.

Our colleague Dr. Birgit Schumacher, Managing Director of GBA Pharma, was elected as the new President of the German Association of Independent Testing Laboratories (VUP) on June 25, 2025 at the annual conference in Berlin. elected. With immediate effect, she is assuming a central role in the industry association of private testing and calibration laboratories in Germany.

The Laboratorium für Klinische Forschung GmbH (LKF), a member of the GBA Group, will now operate under the new company brand GBA Central Lab Services GmbH (GBA CLS). The rebranding initiative represents a strategic direction aimed at aligning the company’s identity with the global GBA Group and at communicating the core service with the company name. It reflects a clear commitment to enhancing international visibility, creating a consistent brand presence across all markets, and positioning GBA Central Lab Services GmbH as a unified and globally recognized provider of central laboratory services.

Eureka Analytical Services Pvt Ltd (Eureka), a subsidiary of the GBA Group, acquires a majority stake in Teena Biolabs Pvt Ltd (Teena), a leading pharmaceutical analytics service provider in India. The acquisition is another important step in the GBA Group's global expansion strategy. Through the merger with Teena, Eureka will become a leading service provider for pharmaceutical analysis in India with a total of two US-FDA approved sites.

Rob Lotthrincx has started as the new Managing Director of ABF Pharmaceutical Services GmbH (ABF) in Vienna on August 1st, 2024.

Dear Rob, it is so great to see that you have been so well received. We are font to have you, your many years of experience as a leader and your profound expertise in pharma logistics and supply chain management on board.